AML-derived exosomes are rich in CD33, CD34, and CD117, and their overall protein content is significantly higher than that of healthy controls; the content of some proteins, such as TGF-β1, decreases at the initial diagnosis and effective treatment of AML and can thus be used for detecting leukemia relapse and drug resistance status (97). The gene discussed is CD33; the disease is leukemia.